Table 1.
Baseline patient characteristics
| SSA (N = 182) |
IFN (N = 97) |
PRRT (N = 105) |
|
|---|---|---|---|
| Sex | |||
| Female | 73 (40.1%) | 40 (41.2%) | 40 (38.1%) |
| Male | 109 (59.9%) | 57 (58.8%) | 65 (61.9%) |
| Age at start (median [IQR]) | 64.7 [58.3;71.5] | 60.9 [53.7;68.2] | 65.9 [58.4;71.1] |
| Resection of primary tumour/lymph nodes | |||
| No | 47 (26.4%) | 20 (20.8%) | 20 (19.2%) |
| Yes | 131 (73.6%) | 76 (79.2%) | 84 (80.8%) |
| Metastasectomy | |||
| No | 122 (67.0%) | 56 (57.7%) | 64 (61.0%) |
| Yes | 60 (33.0%) | 41 (42.3%) | 41 (39.0%) |
| Performance status (WHO) | |||
| 0 | 65 (58.0%) | 34 (58.6%) | 52 (54.7%) |
| 1 | 31 (27.7%) | 15 (25.9%) | 33 (34.7%) |
| 2 | 12 (10.7%) | 8 (13.8%) | 9 (9.5%) |
| ≥3 | 4 (3.6%) | 1 (1.7%) | 1 (1.1%) |
| Ki-67 (median [IQR]) | 7% [4%;10%] | 6% [4%;10%] | 8% [5%;12%] |
| Bone/lung metastases | |||
| No | 114 (75.5%) | 50 (67.6%) | 49 (49.0%) |
| Yes | 37 (24.5%) | 24 (32.4%) | 51 (51.0%) |
| Line of treatment | |||
| 1 | 168 (93.3%) | 60 (62.5%) | 9 (8.7%) |
| 2 | 12 (6.7%) | 29 (30.2%) | 60 (57.7%) |
| ≥3 | 0 (0.0%) | 7 (7.3%) | 35 (33.7%) |
| Concomitant start SSA/other | |||
| No | 112 (63.3%) | 35 (41.7%) | 96 (91.4%) |
| Yes | 65 (36.7%) | 49 (58.3%) | 9 (8.6%) |
| Baseline CgA, × ULN (median [IQR]) | 6.8 [2.1;34.0] | 8.0 [2.2;45.2] | 16.5 [4.5;32.0] |
| Baseline CgA, dichotomized | |||
| <5 | 49 (40.5%) | 31 (43.7%) | 27 (26.7%) |
| 5–10 | 17 (14.0%) | 6 (8.5%) | 12 (11.9%) |
| >10 | 55 (45.5%) | 34 (47.9%) | 62 (61.4%) |
| Baseline 5HIAA, × ULN (median [IQR]) | 4.6 [1.3;15.5] | 4.2 [1.1;15.0] | 6.1 [2.7;15.0] |
| Baseline 5HIAA, dichotomized | |||
| <5 | 68 (55.3%) | 40 (58.0%) | 42 (41.6%) |
| 5–10 | 16 (13.0%) | 7 (10.1%) | 24 (23.8%) |
| >10 | 39 (31.7%) | 22 (31.9%) | 35 (34.7%) |
SSA somatostatin analogues, IFN Interferon-alpha, PRRT peptide receptor radionuclide therapy, CgA chromogranin A, 5HIAA 5-hydroxyindoleacetic acid, ULN upper limit of normal, IQR interquartile range